While it's very possible a few more percent buy and sell within the quarter, they'll not need to report such manipulation. By the time the company is over $5 you'll see Institutional Ownership grow to 30% or more, by $10 the Institution's could become the majority.
Now if a partner in Perifosine also took say a 15% interest in the company, if they were allied with most of the Institutions, effectively they could have control. The least I think such an interest would get is a seat on the BOD. Many years ago a similar move was made at IMCL for 30% of Erbitux as well as 30% of the company, half the shares were tindered, half were newly issued, all told it was to be a $3 billion dollar deal. I frankly believe that Perifosine could be bigger then Erbitux, but then BMY was stung by IMCL's lies about discussions with the FDA and the shares fell as approval was delayed. This is also the cause of the insider trading that put Waksal and Martha Stewart in jail, but my point is that if properly staged, AEZS could bring some very big numbers either for Perifosine, or for AEZS-108 in the not that distant future.
Gary
Market Data 
Markets 
AI
